Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Core Viewpoint - ImmunityBio, Inc. has received approval from the Saudi Food and Drug Authority for ANKTIVA® in combination with Bacillus Calmette-Guérin (BCG) for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ [1] Regulatory Approval - The approval by the SFDA expands the existing approvals for ANKTIVA® in the United States [1]